Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01433172 · ClinicalTrials.gov registry record · Phase 1
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT01433172 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 73 participants.
The verdict
NCT01433172, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) a tumor vaccine used in combination with GM.CD40L and CCL21 have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the immune system of these patients and how their immune system reacts, both before and after the vaccine treatment.
Interventions
- BIOLOGICAL Phase I - GM.CD40L.CCL21 Vaccinations
- BIOLOGICAL Phase II - GM.CD40L cells Vaccinations
- BIOLOGICAL Phase II - GM.CD40L.CCL21 Vaccinations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2012-03-26 |
| Est. Completion | 2019-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01433172
The ClinicalTrials.gov registry entry for NCT01433172 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Phase I - GM.CD40L.CCL21 Vaccinations is the first listed.
NCT01433172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01433172 about?
NCT01433172 is a clinical study titled "Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer". The purpose of this study is to find out what effects (good and bad) a tumor vaccine used in combination with GM.CD40L and CCL21 have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the immune system of these patients and how their immune system react...
What is the current status of trial NCT01433172?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2012-03-26. Estimated completion is 2019-02-01.
What interventions are being tested in trial NCT01433172?
The interventions under investigation include: Phase I - GM.CD40L.CCL21 Vaccinations (BIOLOGICAL), Phase II - GM.CD40L cells Vaccinations (BIOLOGICAL), Phase II - GM.CD40L.CCL21 Vaccinations (BIOLOGICAL).
Who is sponsoring clinical trial NCT01433172?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.